How Laboratory Services Companies Are Valued
I've worked on lab deals across the spectrum — from $8M-revenue regional reference labs to $200M-revenue specialty molecular platforms — and the variance in multiples is enormous. A clinical reference lab and a molecular diagnostics platform are entirely different asset classes that happen to share a CLIA certificate. Buyers don't value them on the same metrics, and you shouldn't either.
The Three Lab Categories
Independent clinical reference labs run high-volume, low-margin testing for hospitals, physician offices, and other labs. EBITDA margins of 12-20% are typical. Multiples land at 6-10x EBITDA — at the low end for sub-$25M revenue regional labs with payer concentration risk, at the high end for $50M+ revenue labs with diversified payer mix and automated chemistry/hematology platforms. The acquirers here are Labcorp (LH), Quest Diagnostics (DGX), Sonic Healthcare, and regional consolidators.
Specialty/anatomic pathology and molecular labs trade at premium multiples of 10-15x EBITDA. Anatomic pathology, dermatopathology, urology pathology, and women's health labs all sit here. The driver is referral relationship stickiness — pathologist sign-out preferences are sticky, and switching costs are real. Acquirers: NeoGenomics, Caris Life Sciences, Aurora Diagnostics (now LabCorp), and PE-backed platforms like Inform Diagnostics.
Molecular diagnostics platforms with proprietary assays operate on a different valuation framework entirely — these are revenue-based deals at 12-25x revenue because the gross margins (60-80%) and TAM look more like specialty pharma than lab services. Companies like Foundation Medicine ($2.4B Roche), Veracyte, Exact Sciences, and Natera define this segment. Premium acquirers: Roche Diagnostics, Thermo Fisher, Illumina, and large pharma.
Public Comps and What They Tell Us
Labcorp (LH) trades at 8-12x EBITDA, Quest Diagnostics (DGX) at 8-11x. Both are stable, scaled, low-growth businesses. NeoGenomics (NEO) trades at higher revenue multiples (3-5x revenue) because of specialty oncology testing growth. Natera (NTRA) and Exact Sciences (EXAS) trade on revenue/growth narratives entirely, not EBITDA.
For SMB lab sellers, the publics are a useful ceiling reference but the relevant comps are private deals. PE consolidators have been actively rolling up specialty lab platforms at 10-13x EBITDA over the past 24 months. The bid range on a $5-25M EBITDA specialty molecular lab with payer contracts and a defensible niche has been 9-12x in deals I've been close to.
Key Value Drivers I Look For
Payer mix and contract status is the first thing buyers diligence. In-network contracts with the major commercial payers (UHC, Anthem, Aetna, Cigna, BCBS plans) are essential. A lab without commercial in-network status is doing 30-50% lower realized rates and faces existential risk if it ever loses Medicare. Buyers will discount aggressively for any out-of-network exposure above 15-20% of revenue.
Test menu defensibility drives multiple expansion. Proprietary or laboratory-developed tests (LDTs) with strong clinical adoption and limited competing assays command premiums. The FDA's evolving LDT regulatory framework is now a real diligence question — labs with FDA-cleared assays carry premium value over LDT-only labs.
Automation and per-test cost matter enormously at scale. Buyers will diligence cost-per-test by panel and benchmark against their internal cost structure. A reference lab running $7 per CMP versus a buyer's $4 per CMP signals integration opportunity but also limits what the buyer will pay — they need synergy room.
Sales channel and pathologist relationships drive specialty lab value. For anatomic pathology and molecular labs, the urology/derm/GI/oncology referral relationships are the asset. Buyers diligence client concentration, average revenue per referring physician, and contract terms. Concentration above 25% in any single referral source is a discount.
What Decreases Laboratory Value
CMS PAMA reimbursement risk is the biggest existential threat to independent labs. The Protecting Access to Medicare Act mandated rate cuts that have already eliminated billions in lab revenue industry-wide. Future PAMA cycles remain a valuation overhang for any lab with significant Medicare exposure. Buyers price this in with discounted forward multiples on Medicare revenue.
Out-of-network billing exposure is a deal killer. The No Surprises Act and state surprise billing legislation have eliminated balance billing as a viable strategy. Labs that built revenue on out-of-network rates are being repriced down.
FDA LDT regulatory risk is the new wild card. The FDA's 2024 final rule phasing in LDT oversight creates uncertainty for labs with significant LDT-only revenue. Buyers want to see a regulatory pathway plan or FDA submissions in progress.